Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7287099 | 1.00 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL9109723 | 1.00 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL22779705 | 0.86 | — | — | |
| SCHEMBL11794881 | 0.81 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL9432212 | 0.78 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL10565853 | 0.76 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL10565859 | 0.76 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL11792753 | 0.75 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL498419 | 0.75 | NAAA (0.40) | ALDH1A1 | |
| SCHEMBL498418 | 0.75 | NAAA (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | ViiV Healthcare UK (No.4) Limited (GB) | 2022-10-11 | — | — | US | disclosed |
| EP-3750910-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV Healthcare UK(No.4) Limited (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2020-11-19 | — | — | US | disclosed |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2020-11-19 | — | — | US | disclosed |
| US-10780102-B2 | Triterpenoids with HIV maturation inhibitory activity | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| EP-3129392-B1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-08-05 | — | — | EP | disclosed |
| US-20190151336-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-23 | — | — | US | disclosed |
| US-10245275-B2 | Triterpenoids with HIV maturation inhibitory activity | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2019-04-02 | — | — | US | disclosed |
| US-10245275-B2 | Triterpenoids with HIV maturation inhibitory activity | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2019-04-02 | — | — | US | disclosed |
| US-20170340650-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2017-11-30 | — | — | US | disclosed |
| US-20120142653-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| WO-2011153319-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-08 | — | — | WO | disclosed |
| US-5952334-A | SORDARIN DERIVATIVES; FUNGICIDES | GLAXO WELLCOME S.A. (ES) | 1999-09-14 | — | — | US | disclosed |
| EP-0753001-B1 | ANTIFUNGAL SORDARIDIN DERIVATIVES | GLAXO WELLCOME SA (ES) | 1999-09-08 | — | — | EP | disclosed |
| US-5854280-A | Antifungal sordaridin derivatives | GLAXO WELLCOME S.A. (ES) | 1998-12-29 | — | — | US | disclosed |
| EP-0711784-A1 | Antifungal Sordarin derivatives | GLAXO, S.A. (ES) | 1996-05-15 | — | — | EP | disclosed |
| US-5506262-A | ANTICHOLESTEROL AGENTS, FUNGICIDES, ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-04-09 | — | — | US | disclosed |
| US-5468778-A | Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl) 5-heptenoic acids and derivatives | ALLERGAN, INC. (US) | 1995-11-21 | — | — | US | disclosed |
| WO-1992020336-A2 | NOVEL CHOLESTEROL LOWERING COMPOUNDS | MERCK & CO., INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0512865-A2 | Novel cholesterol lowering compounds | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780102-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
| US-11464790-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
| US-20190151336-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
| US-10245275-B2 | Triterpenoids with HIV maturation inhibitory activity | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
| US-20120142653-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | ERG28, BET1, BRD3 | ALDH1A1 3288/4885 |
| US-20200360404-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
| US-20170340650-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CYP8B1, LSS | ALDH1A1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.